Is Jisandai (Bingtonsha) hepatotoxic?

Epclusa (Epclusa), composed of Sofosbuvir (Sofosbuvir) and Velpatasvir (Velpatasvir), is a drug used to treat hepatitis C. Overall, Jisandai (Bingtonsa) has low hepatotoxicity and is widely regarded as safe. However, like all medicines, in rare cases, Bingtonsa may have an effect on the liver.

The main function of Jisandai (Bingtonsha) is to inhibit the replication of hepatitis C virus, thereby reducing the damage of the virus to the liver. In most patients, Bingtonsa can effectively control the virus and improve liver function without significant hepatotoxicity. However, in some cases, patients may experience abnormalities in liver function indicators, which may be related to individual differences or comorbidities.

In clinical trials and actual use, Jisandai (bingtonsa) generally does not cause significant hepatotoxicity. However, patients still need to monitor liver function regularly during treatment. Especially for those patients with cirrhosis or other serious liver diseases, doctors may pay more attention to changes in liver function and make adjustments as needed.

Jisandai (Bingtonsa) generally exhibits fewer side effects than traditional treatment options. Despite this, patients may still experience some side effects, such as headache, fatigue, nausea, etc. when using GISANDA (Bingtonsa). These side effects are usually mild and tolerated by most patients. If patients experience serious side effects or abnormal liver function, they should communicate with their doctor in time so that appropriate measures can be taken.

In addition, special attention needs to be paid to the fact that in a small number of patients, Bingtonsa may interact with other medications or underlying health problems, causing abnormal liver function. Especially in patients taking other medications concurrently or with a history of liver disease, treatment adjustments or closer monitoring may be needed.